Cardiac contractility modulation in HFrEF patients with QRS duration 120-149 ms: reduction in heart failure hospitalizations and improvement in functional outcome

Heart Failure

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Circulation

Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, Kuder JF, Desai AS, Inzucchi SE, McMurray JJV, O'Meara E, Verma S, Bělohlávek J, Drożdż J, Merkely B, Ogunniyi MO, Drasnar T, Izzo JL, Sarman B, McGinty JE, Ramanathan K, Mulkay AJ, Przybylski A, Ruff CT, O'Donoghue ML, Murphy SA, Sabatine MS, Wiviott SD, DAPA ACT HF-TIMI 68 Trial Committees and Investigators

doi: 10.1161/CIRCULATIONAHA.125.076575

Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Eur J Heart Fail

Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C

doi: 10.1002/ejhf.3565

ESC 2025

Heart Failure

Treating heart failure patients with anti-obesity medication reduces greenhouse gas emissions and improves clinical outcomes

Heart Failure

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

Eur J Heart Fail

Ameri P, Costa P, Benson L, Stolfo D, Sayour NV, Ljungman C, Butler J, Anker SD, Girerd N, Keramida K, Filippatos G, Lund LH, Lindberg F, Savarese G

doi: 10.1002/ejhf.3775

Heart Failure

Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction

J Am Coll Cardiol

Min KH, Go AS, Lee K, Parikh RV, Horiuchi KM, Ambrosy AP, Tan TC, Srikanth K, Hamilton SA, Svetlichnaya J, Solomon SD, Inciardi RM, Vardeny O, Vasti E, Sandhu AT, Ku IA, Adatya S, Bhatt AS

doi: 10.1016/j.jacc.2025.05.040

Heart Failure

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

PLoS One

Bitos K, Laptseva N, Haider T, Rossi VA, Nägele MP, Barthelmes J, Ruschitzka F, Sudano I, Flammer AJ

doi: 10.1371/journal.pone.0325668

Heart Failure

In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial

J Am Heart Assoc

Nouhravesh N, Cyr D, Hernandez AF, Morrow DA, Velazquez EJ, Ward J, Sarwat S, Sharma K, Williamson K, Starling RC, Lepage S, Zieroth S, Solomon SD, Mentz RJ

doi: 10.1161/JAHA.124.037899

Heart Failure

Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study

Clin Res Cardiol

Ojeda-Fernández L, Torrigiani G, Molteni M, Fortino I, Cimminiello C, Baviera M

doi: 10.1007/s00392-025-02674-9

Heart Failure

Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score

J Am Heart Assoc

Abassi NK, Nouhravesh N, Elmegaard M, Austreim M, Zahir D, Garred CH, Butt JH, Andersen CF, Strange JE, Sindet-Pedersen C, Christensen DM, Fosbøl E, Andersson C, Køber L, Schou M

doi: 10.1161/JAHA.124.037973

Related content

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Treating heart failure patients with anti-obesity medication reduces greenhouse gas emissions and improves clinical outcomes

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial

Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study

Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score